Cargando…

Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial

INTRODUCTION: In early breast cancer, neoadjuvant chemotherapy (NACT) is increasingly used. The proof of efficacy is pathologically complete response (pCR), i.e. the absence of invasive tumour in breast and lymph nodes at surgery. Today, pCR is a common endpoint in pharmaceutical trials since it is...

Descripción completa

Detalles Bibliográficos
Autores principales: de Boniface, Jana, Altena, Renske, Haddad Ringborg, Cecilia, Bolam, Kate A., Wengström, Yvonne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562167/
https://www.ncbi.nlm.nih.gov/pubmed/36227931
http://dx.doi.org/10.1371/journal.pone.0274804
_version_ 1784808108973883392
author de Boniface, Jana
Altena, Renske
Haddad Ringborg, Cecilia
Bolam, Kate A.
Wengström, Yvonne
author_facet de Boniface, Jana
Altena, Renske
Haddad Ringborg, Cecilia
Bolam, Kate A.
Wengström, Yvonne
author_sort de Boniface, Jana
collection PubMed
description INTRODUCTION: In early breast cancer, neoadjuvant chemotherapy (NACT) is increasingly used. The proof of efficacy is pathologically complete response (pCR), i.e. the absence of invasive tumour in breast and lymph nodes at surgery. Today, pCR is a common endpoint in pharmaceutical trials since it is significantly associated with survival especially in triple-negative and HER2-positive subtypes. Apart from the mitigation of treatment-related toxicity and symptoms, physical exercise mediates anti-tumoral systemic effects associated with tumour regression in preclinical and clinical models. The aim of Neo-ACT is to test the hypothesis that physical exercise can improve pCR rates in breast cancer patients receiving NACT. METHOD: The Neo-ACT trial is a prospective clinical trial, randomising T1-3N0-2 breast cancer patients planned for NACT to either a home-based physical exercise intervention supported by a mobile application or routine care. The primary endpoint is pCR; secondary endpoints are patient-reported quality of life, toxicity-related outcomes, and oncological outcomes such as Residual Cancer Burden, objective radiological tumour response, as well as overall, breast cancer-specific and disease-free survival at 2, 5 and 10 years. The intervention consists of a combination of high-intensity interval and resistance training of progressing intensity, and includes at least 150 min of moderate to vigorous physical activity per week, inclusive of two weekly 60-min exercise sessions. In order to show an improvement in pCR of 10%, a total of 712 participants need to be included in the analysis. The Neo-ACT has been registered at clinicaltrials.gov on January 11, 2022 (NCT05184582). EXPECTED RESULTS: If Neo-ACT can prove the oncological efficacy of physical exercise, implementation of training programmes into NACT schedules will be pursued. The use of a digitally led exercise intervention aims to test the potential of such a strategy for use in rural areas and areas of limited resources.
format Online
Article
Text
id pubmed-9562167
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-95621672022-10-15 Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial de Boniface, Jana Altena, Renske Haddad Ringborg, Cecilia Bolam, Kate A. Wengström, Yvonne PLoS One Study Protocol INTRODUCTION: In early breast cancer, neoadjuvant chemotherapy (NACT) is increasingly used. The proof of efficacy is pathologically complete response (pCR), i.e. the absence of invasive tumour in breast and lymph nodes at surgery. Today, pCR is a common endpoint in pharmaceutical trials since it is significantly associated with survival especially in triple-negative and HER2-positive subtypes. Apart from the mitigation of treatment-related toxicity and symptoms, physical exercise mediates anti-tumoral systemic effects associated with tumour regression in preclinical and clinical models. The aim of Neo-ACT is to test the hypothesis that physical exercise can improve pCR rates in breast cancer patients receiving NACT. METHOD: The Neo-ACT trial is a prospective clinical trial, randomising T1-3N0-2 breast cancer patients planned for NACT to either a home-based physical exercise intervention supported by a mobile application or routine care. The primary endpoint is pCR; secondary endpoints are patient-reported quality of life, toxicity-related outcomes, and oncological outcomes such as Residual Cancer Burden, objective radiological tumour response, as well as overall, breast cancer-specific and disease-free survival at 2, 5 and 10 years. The intervention consists of a combination of high-intensity interval and resistance training of progressing intensity, and includes at least 150 min of moderate to vigorous physical activity per week, inclusive of two weekly 60-min exercise sessions. In order to show an improvement in pCR of 10%, a total of 712 participants need to be included in the analysis. The Neo-ACT has been registered at clinicaltrials.gov on January 11, 2022 (NCT05184582). EXPECTED RESULTS: If Neo-ACT can prove the oncological efficacy of physical exercise, implementation of training programmes into NACT schedules will be pursued. The use of a digitally led exercise intervention aims to test the potential of such a strategy for use in rural areas and areas of limited resources. Public Library of Science 2022-10-13 /pmc/articles/PMC9562167/ /pubmed/36227931 http://dx.doi.org/10.1371/journal.pone.0274804 Text en © 2022 de Boniface et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Study Protocol
de Boniface, Jana
Altena, Renske
Haddad Ringborg, Cecilia
Bolam, Kate A.
Wengström, Yvonne
Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial
title Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial
title_full Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial
title_fullStr Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial
title_full_unstemmed Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial
title_short Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial
title_sort physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: trial protocol of the randomized neo-act trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562167/
https://www.ncbi.nlm.nih.gov/pubmed/36227931
http://dx.doi.org/10.1371/journal.pone.0274804
work_keys_str_mv AT debonifacejana physicalexerciseduringneoadjuvantchemotherapyforbreastcancerasameantoincreasepathologicalcompleteresponseratestrialprotocoloftherandomizedneoacttrial
AT altenarenske physicalexerciseduringneoadjuvantchemotherapyforbreastcancerasameantoincreasepathologicalcompleteresponseratestrialprotocoloftherandomizedneoacttrial
AT haddadringborgcecilia physicalexerciseduringneoadjuvantchemotherapyforbreastcancerasameantoincreasepathologicalcompleteresponseratestrialprotocoloftherandomizedneoacttrial
AT bolamkatea physicalexerciseduringneoadjuvantchemotherapyforbreastcancerasameantoincreasepathologicalcompleteresponseratestrialprotocoloftherandomizedneoacttrial
AT wengstromyvonne physicalexerciseduringneoadjuvantchemotherapyforbreastcancerasameantoincreasepathologicalcompleteresponseratestrialprotocoloftherandomizedneoacttrial